This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Polypore International's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Contrasting this to where we were virtually one year ago, recall that our businesses were operating at maximum capacity utilization with limited or no upside due to those capacity constraints. In fact, in some cases, we were turning away business. And at that point in time, we were accelerating and aggressively funding major capital investments and capacity expansions.

So we understand the cost of not having capacity especially in growth markets. Given the choice of where we are today compared to last year, we prefer to have capacity available. We're bearing some added costs as a result of that and while those costs are very transparent in our financial with the current level of sales, the value of having in our capacity will be very impactful when those incremental sales occur.

And it enables us to be highly responsive to an upturn in demand. Additionally, with the majority of our cash spent for these investments now behind us, we're positioned for substantial cash generation and substantial earnings growth potential going forward and we remain keenly focused on executing to meet the growing global demand for our products.

In the lead acid business, the future is in Asia which is the fastest growing region in the world. We've taken methodical and strategic actions over the past several years to be well positioned there. Today we serve the fastest growing customers in Asia. We have the largest facility and production capability in the region with more capacity beginning to ramp up in Thailand and China. And we have the most established infrastructure to service this region including manufacturing, sales, technical support and R&D as well as distribution capability.

In healthcare with the additional PUREMA capacity that was recently installed, we're well positioned to capitalize on current and future demand in hemodialysis membranes and we anticipate demand across our healthcare applications to remain solid.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs